SCHEMBL2910364

SCHEMBL2910364

COc1cc(N(Cc2cccnc2)c2ccc(C(=O)O)cc2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.46
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NAMPT P43490 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
TSHR P16473 1/20 0.43
BLM P54132 1/20 0.43
GRM2 Q14416 1/20 0.43
NR3C2 P08235 1/20 0.43
HTT P42858 2/20 0.42
MAPT P10636 1/20 0.42
CYP2C19 P33261 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
LPAR1 Q92633 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910411 0.92 GRM2 (0.46) TAS2R14ALDH1A1NPSR1L3MBTL1NAMPT
SCHEMBL2905935 0.92 HTT (0.48) TAS2R14ALDH1A1NPSR1L3MBTL1NAMPT
SCHEMBL4190538 0.90 ALDH1A1 (0.55) TAS2R14ALDH1A1NPSR1L3MBTL1USP2
SCHEMBL2909130 0.88 KMT2A (0.46) ALDH1A1NPSR1L3MBTL1NAMPTUSP2
SCHEMBL4188436 0.86 ALDH1A1 (0.47) ALDH1A1NPSR1L3MBTL1USP2CYP1A2
SCHEMBL3131330 0.86 ALDH1A1 (0.46) ALDH1A1NPSR1L3MBTL1USP2CYP1A2
SCHEMBL3123134 0.86 ALDH1A1 (0.46) ALDH1A1NPSR1L3MBTL1USP2CYP1A2
SCHEMBL4193526 0.86 L3MBTL1 (0.48) ALDH1A1NPSR1L3MBTL1USP2CYP1A2
SCHEMBL3129550 0.86 TSHR (0.52) ALDH1A1NPSR1L3MBTL1USP2CYP1A2
SCHEMBL2908505 0.85 NPC1 (0.47) ALDH1A1NPSR1L3MBTL1NAMPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B TAS2R14 3203/4885ALDH1A1 300/4885NPSR1 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.